Meeting
2014 ASCO Annual Meeting
First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors.
Authors
Hui Kong Gan
Austin Health, Heidelberg, Australia
Hui Kong Gan , Jason Lickliter , Michael Millward , Yi Gu , Weiguo SU , Melanie Frigault , Chuan Qi , Hua MU
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
New Targets and New Technologies
Clinical Trial Registration Number
NCT01773018
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11111)
DOI
10.1200/jco.2014.32.15_suppl.11111
Abstract #
11111
Poster Bd #
393
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.
First Author: Shunsuke Kondo
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
First Author: Christian K. Kollmannsberger
Poster
2015 ASCO Annual Meeting
First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
First Author: Philippe L. Bedard